NCT05794191Completed
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
Assessment of 13-valent Pneumococcal Conjugate Vaccine Effectiveness Among People With HIV in the United States
Source: ClinicalTrials.gov · Last updated 20 Oct 2025
Brief summary (registry, in English)
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 350399 (actual)
- First submitted
- 20 Mar 2023
- Start date
- 22 Mar 2023
- Primary completion date
- 15 Aug 2024
- Lead sponsor
- Pfizer
- Diseases
- HIV
- NCT number
- NCT05794191
What you commit to
- Study type: Observational
- Participants enrolled: 350399
- From 22 Mar 2023 to the primary completion date, 15 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Evidence of PCV13 vaccination before the first HIV-related code
Who the study is looking for
- HIV infection defined as at least one inpatient or ≥2 outpatient codes related to HIV at least 30 days but no more than 730 days apart
- At least 18 years of age at the time of the first HIV-related code
- At least six months of continuous enrollment in medical and pharmacy plans after the first HIV-related code
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.